Previous studies have revealed that bone marrow-mesenchymal stem cells (BM-MSCs) from systemic lupus erythematosus (SLE) patients exhibited early signs of senescence, which may participate in the development of SLE. However, the molecular mechanisms about this phenomenon have not been fully elucidated. In the current study, we aimed to investigate whether Janus kinase (JAK)-signaling transducers and activators of transcription (STAT) signaling mediated the senescence of BM-MSCs from SLE patients. Twelve female SLE patients and healthy subjects were enrolled in the study. All BM-MSCs were isolated by density gradient centrifugation. Western blot analysis was used to test the expression of JAK-STAT signaling molecules. We observed the activity of β-gal of cells, the changes of cytoskeletal structure by F-actin staining, and the distribution of cell cycle by flow cytometry. BM-MSCs from SLE patients showed prominent features of senescence, and abnormal activation of JAK-STAT signaling transduction, high level of phosphorylated JAK2, and STAT3. After stimulation of IFN-γ in normal MSCs, JAK-STAT signaling was activated. The cell volume and the number of senescence-associated β-galactosidase (SA-β-gal) positive in SLE BM-MSCs were increased. The organization of cytoskeleton was nearly disordered. The rate of cell proliferation was decreased. AG490, the inhibitor of JAK2, and knockdown of STAT3 in BM-MSCs, could significantly reverse the senescence. In summary, our study indicated that JAK-STAT signaling pathway may play a critical role in the senescence of SLE BM-MSCs.
Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease characterized by multi-organ involvement and a remarkable variability in clinical presentation [1] . It is a typical autoimmune disease based on the variety of its proposed pathogenesis, including abnormalities of T and B lymphocytes. Bone marrow-mesenchymal stem cells (BM-MSCs) are multipotent stem cells with the capacity for self-renewal and the potential to differentiate into a variety of cell types, including osteoblasts, chondrocytes, and adipocytes [2] . BM-MSCs have been found to possess immunomodulatory effects on various activated immune cells, such as T cells, B cells, natural killer cells, and dendritic cells [3, 4] . Additionally, BM-MSCs are able to escape alloantigen recognition because of their low immunogenicity and accompanying lack of expression of costimulatory molecules [5] . The functional features of BM-MSCs make them attractive therapeutic targets for SLE. Our studies and others have revealed that allogenic MSC transplantation (MSCT) appears to be a feasible and safe therapeutic strategy in lupus-prone mice and SLE patients [6] [7] [8] [9] [10] [11] . However, syngeneic MSCT was ineffective [11, 12] . Recently, we reported that BM-MSCs from both untreated and treated SLE patients showed characteristics of senescence [13] . These studies revealed that senescent BM-MSCs may be associated with the pathogenesis of SLE, but the molecular mechanisms were not very clear. The identification of the molecular mechanisms by which senescent BM-MSCs lead to SLE has the important significance.
The evolutionary conserved Janus kinase (JAK)-signaling transducers and activators of transcription (STAT) signaling pathway are used by a variety of cytokines, hormones, and growth factors to regulate numerous developmental and homeostatic processes, including hematopoiesis, immune cell development, stem cell maintenance, and organismal growth [14] . In addition, JAK-STAT signaling pathway has been reported to be involved in cellular senescence [15] . The two types of IFNs, Type I (represented by IFN-α family, IFN-β, IFN-ω, and IFN-τ) and Type II (represented by IFN-γ only) bind to their specific plasma membrane receptors, thereby initiating a cascade of events known as the JAK/STAT signaling pathway [15] . The increased levels of circulatory inflammatory markers, including IFN-γ, IL-1β, IL-6, and TNF-α, are known to be associated with senescence [16] . IFN-γ was previously shown to induce cellular senescence in human endothelial cells [17] . IFN-γ is also an important cytokine in bone marrow micro-environment [18] . However, whether IFN-γ triggered the senescence of BM-MSCs in bone marrow micro-environment from SLE patients through JAK-STAT pathway remained unclear.
In this study, we further confirmed that BM-MSCs from SLE patients are senescent. The roles of JAK-STAT signaling on the senescence of SLE BM-MSCs were investigated. We found that the expression levels of p-JAK2 and p-STAT3 were higher in SLE BMMSCs than in the normal groups. Different concentrations of IFN-γ were used to stimulate BM-MSCs, resulting in the activation of JAK-STAT signaling pathway and the senescence of BM-MSCs. In addition, to further evaluate the effects of JAK-STAT signaling on the senescence of SLE BM-MSCs, we used 100 μM AG490 and STAT siRNA to reverse the senescent features of SLE BM-MSCs.
Materials and Methods

Patients
Twelve SLE patients aged between 18 and 43 years (mean 27.67 ± 7.32 years) were enrolled in this study ( Table 1 ). The SLE diagnosis was made based on the criteria proposed by the American College of Rheumatology (Hochberg 1997). The Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) was used to measure the disease activity. All patients were categorized as active using a cut-off SLEDAI score of eight. Twelve healthy subjects were used as the normal group. All research subjects were females with a similar age distribution (mean 27.50 ± 7.76 years). All participators signed the consent to the study, which was approved by the Ethics Committee of the Affiliated Hospital of Nantong University (Nantong, China).
Isolation, cell culture, and identification of BM-MSCs from SLE and normal subjects MSCs were isolated and expanded from iliac crest BM of all the SLE patients and normal subjects. Five milliliters of heparinized BM were mixed with an equal volume of phosphate-buffered saline (PBS). Then, the resuspended cells were layered over Ficoll solution (1.077 g/ml) and centrifuged at 1000 g for 30 min at 24°C. The mononuclear cells were collected at the interface and resuspended in low-glucose Dulbecco Modified Eagle Medium (HyClone, Logan, USA) supplemented with 10% heat inactivated fetal bovine serum (FBS; Gibco, Carlsbad, USA). Then, the cells were plated at a density of 2 × 10 7 cells per 25 cm 2 dish and cultured at 37°C in a 5% CO 2 incubator, and the medium was replaced and non-adherent cells were removed after 5 days and every 3 days thereafter. When the MSCs became nearly confluent, the adherent cells were released from the dishes with 0.25% trypsinethylenediaminetetraacetic acid (Gibco), and then replanted at a density of 1 × 10 6 cells per 25 cm 2 dish. Flow cytometric analysis showed that the cells were positive for CD29, CD44, CD105, and CD166, but negative for CD14, CD34, CD38, CD45, and HLA-DR. After Passages 4 (p4), cells were used for the subsequent studies.
Western blot analysis
Cells were washed twice with cold PBS and lysed in radio immunoprecipitation assay buffer consisting of 50 mM Tris, 150 mM NaCl, 2% sodium dodecyl sulfate (SDS), and a protease inhibitor mixture. Equal amounts of protein were separated by 10% SDS polyacrylamide gel electrophoresis and electrophoretically transferred to polyvinylidene difluoride membranes. Membranes were blocked with 5% non-fat milk or 5% bovine serum albumin and incubated with primary antibodies (1:500) at 4°C overnight and incubated with the corresponding horseradish peroxidase-conjugated secondary antibody (1:2000) for 2 h at room temperature. The blots were developed using an enhanced chemiluminescence kit (Beyotime, Haimen, China). The following primary antibodies were used: rabbit anti-GAPDH Ab, goat anti-p-JAK2 Ab, mouse anti-p-STAT3 Ab, rabbit anti-JAK2 Ab, rabbit anti-STAT3 Ab, mouse anti-CDK2 Ab, rabbit anti-CyclinD1 Ab, mouse anti-CyclinE Ab, and mouse antip21 Ab. All of the primary antibodies were from Santa Cruz (Santa Cruz, USA).
SA-β-gal assay
The senescence-associated β-galactosidase (SA-β-gal) activity was determined using a kit from the Chemical Company (Beyotime) following the manufacturer's instructions. MSCs were passaged into the six-well culture plates at a density of 5 × 10 4 cells per well for 72 h. Then cells were washed twice with PBS and fixed with fixation solution for 15 min. After incubation with SA-β-gal staining solution at 37°C without CO 2 overnight, the slips were washed and analyzed under the microscope.
Immunofluorescence assay of the skeleton of MSCs
MSCs were washed twice with PBS and fixed with 4% paraformaldehyde for 1 h. After permeabilization and blocking, the cells were incubated with fluorescein isothiocyanate-conjugated phalloidin (Thermo Fisher, Waltham, USA). The stained cells were then examined with a Zeiss Confocal Laser Scanning Microscope (Oberkochen, Germany).
Flow cytometry analysis
For cell cycle analysis, MSCs were collected and fixed with 70% ethanol at −20°C for 24 h. After being washed with PBS, cells were treated with 100 µg/ml RNase (Sigma, St Louis, USA) for 20 min and then stained with 50 µg/ml propidium iodide solution (Sigma) for 20 min, and finally analyzed by the flow cytometry (FACS Calibur, BD Biosciences, San Diego, USA). The fraction of cells in the G0/G1, S, and G2/M phases were quantified with the ModFit LT system.
siRNA transfection BM-MSCs (2.5 × 10 5 cells) were seeded in 6-cm dish and cultured in MEM-α medium containing 10% FBS (Gibco) for 1 day. The BMMSCs were then transfected with STAT3-siRNA (GenePharma Co. Ltd, Shanghai, China) or a non-specific control siRNA. The siRNA targeting the nucleotide residues 5′-CTGCTAAGATTCAGTGAAA-3′ was named as si#1, 5′-GCGTCCAGTTCACTACTAA-3′ as si#2, 5′-T CAGCACAATCTACGAAGA-3′ as si#3. Transient transfection was performed using the transfection reagent Lipofectamine 2000 (Invitrogen, Carlsbad, USA) according to the manufacturer's protocol.
Statistical analysis
All data are presented as the mean ± standard deviation from at least three independent experiments. All statistical analyses were performed using the SPSS 21.0 software, and the data were analyzed using Student's t-test. P < 0.05 was considered statistically significant.
Results
The BM-MSCs from SLE patients showed senescence characteristics
The primary culture of BM-MSCs was successful in 12 cases of SLE patients and 12 cases of healthy donors. As previously shown, BMMSCs from SLE patients exhibited senescent behavior [13, 19] . SA-β-gal has been proposed to be a universal marker of senescence. It was found that the number of SA-β-gal-positive cells was significantly increased in the BM-MSCs from SLE patients in comparison with the BM-MSCs from a normal person (Fig. 1A,B) . The F-actin distribution was disordered and assembled around the nuclear region in BM-MSCs from SLE patients (Fig. 1C) . Flow cytometry analysis showed that there were more BM-MSCs restricted in the G1 phase harvested from the treated-and untreated-SLE patients than in the BM-MSCs from the normal patients (Fig. 1D,E) . These results suggested that the BM-MSCs from SLE patients were senescent cells.
JAK-STAT signaling was over-activated in BM-MSCs from SLE patients
To identify the activity of the JAK-STAT signaling pathway in BMMSCs of SLE patients, the p-JAK2 and p-STAT3 expression in the BM-MSCs of the normal and SLE groups were examined by western blot analysis. The results showed that p-JAK2 and p-STAT3 expression was clearly increased in the senescent SLE BM-MSCs compared to the levels in normal persons ( Fig. 2A,B) . These results suggested that over-actived JAK-STAT signaling may be associated with the senescence of SLE BM-MSCs.
IFN-γ increased the expression of JAK-STAT signaling and promoted cellular senescence in normal BM-MSCs
Different concentrations of IFN-γ were used to stimulate BM-MSCs, which resulted in the activation of JAK-STAT signaling pathway and the senescence of BM-MSCs. The results showed that IFN-γ increased p-STAT3 expression at a concentration of 10 ng/ml or higher and achieved maximal effects at doses of 100 ng/ml (Fig. 3A,B) . Thus, 48 h of treatment with 100 ng/ml of IFN-γ was used in the subsequent experiments. Then, the effects of IFN-γ on the senescence of BM-MSCs from SLE patients were explored and the results showed there were more SA-β-gal-positive cells in the BM-MSCs from normal persons when treated with IFN-γ (Fig. 3C) . Furthermore, the distribution of Factin in BM-MSCs from normal persons was disordered after treatment with IFN-γ (Fig. 3D) . Cell cycle analysis indicated that the G1 phase was induced in normal BM-MSCs when treated with IFN-γ (Fig. 3E) . Then, western blot analysis were performed to examine the protein expressions of CDK2, CyclinD1, CyclinE, and negative cell cycle regulator p21 in normal BM-MSCs treated with IFN-γ (Fig. 3F) . Our results showed that IFN-γ increased the expression of JAK-STAT signaling and promoted cellular senescence in normal BM-MSCs, which further implied that the JAK-STAT signaling pathway may play an essential role in the senescence of SLE BMMSCs.
AG490 and si-STAT3 slowed cellular senescence in BM-MSCs from SLE patients
To further assess the role of JAK-STAT signaling in the progression of BM-MSC senescence, different concentrations of AG490, a JAK-STAT signaling inhibitor, were used. The results showed that AG490 inhibited p-STAT3 expression at concentrations of 100 μM or higher and achieved maximal effects at the dose of 500 μM (Fig. 4A) . Thus, 48 h of treatment with 100 μM of AG490 was used in the subsequent experiments. Figure 2 . JAK-STAT signaling was over-activated in BM-MSCs from SLE patients (A,B) p-JAK2 and p-STAT3 expression were higher in BM-MSCs from SLE patients compared with that from the normal group, as determined by western blot analysis. GAPDH was used as an internal control. *P < 0.05 compared with the normal group, # P < 0.05 compared with the normal group.
Next, STAT3-siRNA was used to knockdown the expression of STAT3 in SLE BM-MSCs. SLE BM-MSCs were transfected with STAT3-siRNA #1-3 or control siRNA. After 48 h, STAT3 protein levels were evaluated by western blot analysis. It was found that siRNA #3 significantly knocked down the expression of STAT3 compared with the control siRNA (Fig. 4B) . Besides, there were less SA-β-gal-positive cells in the BM-MSCs from SLE patients when treated with STAT3-siRNA and AG490. Addition of IFN-γ did not increase the ratio of SA-β-gal-positive cells in AG490-treated SLE MSCs (Fig. 4C) . Furthermore, the disordered distribution of F-actin in BMMSCs from SLE patients was effectively reversed after treatment with AG490 and STAT3-siRNA (Fig. 4D) . Cell cycle analysis revealed that the G1 phase arrest was reversed in SLE BM-MSCs treated with AG490 and STAT3-siRNA (Fig. 4E) . The protein expressions of CDK2, CyclinD1, CyclinE, and p21 examined by western blot analysis were in accord with results of cell cycle analysis. These results further implied that the JAK-STAT signaling pathway may play an essential role in the senescence of SLE BM-MSCs.
Discussion
In the present study, we further confirmed that SLE is a stem cell disorder disease [20] [21] [22] [23] . In addition, BM-MSCs from SLE patients displayed prominent senescent characteristics, such as the increased SA-β-gal staining, disordered cytoskeletons, and slowdown growth rates, which were similar to our previous studies. Thus, we speculated that the senescence might be involved with functional abnormalities in BM-MSCs from SLE patients. Our results showed that IFN-γ, an important cytokine in bone marrow micro-environment, promoted the senescence of BM-MSCs and the involvement of JAK-STAT signaling in the senescence of BM-MSCs from SLE patients. Previous studies have shown that JAK-STAT signaling pathway regulates numerous developmental and homeostatic processes, including hematopoiesis, immune cell development, stem cell maintenance, and organismal growth by a variety of cytokines, hormones, and growth factors, such as IFN-γ, IL-6, IL-10, and TNF-α [24] . The biological effects of lymphokine (IL-2, IL-6, and IFN-γ) are mediated by the activation of the STATs. The activation of the latent cytoplasmic protein STATs upon receptor stimulation is mediated by protein tyrosine kinases belonging to the JAK family [25] . Previous evidence has indicated that JAK-STAT signaling has a close relationship with cellular senescence [26] . For instance, Price et al. [26] found that the activation of JAK-STAT signaling in satellite cells significantly contributes to myogenic commitment and results in their regenerative deficiency. Our research group discovered that signaling was overactivated in senescent BM-MSCs from SLE patients. This suggests that JAK-STAT signaling plays an important role in the process of senescence in BM-MSCs from SLE patients.
As we all know, IFN-γ activates JAK tyrosine kinase and STAT transcriptional factor by binding to IFN-γR [24] . We found that different concentrations IFN-γ lead to the phosphorylation of JAK2 and STAT3 in normal mesenchymal stem cells. One remarkable feature of numerous cytokines, especially IFN-γ, is their ability to induce a long-term DNA damage response (DDR) and cellular senescence. Indeed, Hubackova et al. [27] confirmed that treatment with IFN-γ alone persistently activated DDR in both normal and tumor human cells, accompanied by premature senescence. Furthermore, a previous study illustrated that IFN signaling pathways are activated in lupus patients and are tightly correlated with disease activity [28] . Harigai et al. [29] reported that circulating IFN-γ is increased in lupus patients. Then, is IFN-γ involved in the senescence of BM-MSCs from SLE patients? After 48 h of treatment with 100 ng/ml IFN-γ, the number of SA-β-gal-positive cells was significantly increased and the proliferation was obviously weakened.
In summary, our data indicated that JAK-STAT signaling may play a critical role in the senescence of BM-MSCs from SLE patients, which may implicate the possible involvement of BM-MSCs in the pathogenesis of SLE. Interpreting the mechanisms of JAK-STAT signaling involved in the senescence of SLE BM-MSCs will help improve the transplantation efficacy of BM-MSCs in SLE patients.
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